#1 Clinical Trials Search in Europe

Nimorazole

Nimorazole is a drug being studied in clinical trials for the treatment of head and neck squamous cell carcinoma (HNSCC). It belongs to a class of drugs called radiosensitizers, which make tumor cells more sensitive to radiation therapy. Several ongoing trials are evaluating whether adding nimorazole to standard radiation therapy and chemotherapy can improve outcomes for patients with HNSCC, particularly those with more hypoxic (low oxygen) tumors.

Table of Contents

What is Nimorazole?

Nimorazole is a drug that belongs to a class of chemicals known as 5-nitroimidazoles. While drugs from this class are typically used to treat infections, nimorazole has a unique application in cancer treatment[2]. It is primarily used as a radiosensitizer, which means it makes tumor cells more sensitive to radiotherapy[2].

How Nimorazole Works

Nimorazole works by targeting hypoxic areas in tumors. Hypoxia refers to a condition where certain parts of a tumor have low oxygen levels. These hypoxic areas are often resistant to radiotherapy, making the treatment less effective. Nimorazole helps to overcome this resistance by making the hypoxic tumor cells more sensitive to radiation[1]. This process is called hypoxic modification of radiotherapy[1].

Conditions Treated with Nimorazole

Nimorazole is primarily used in the treatment of head and neck squamous cell carcinoma (HNSCC). This is a type of cancer that begins in the flat cells that line the inside of the mouth, nose, throat, and voice box[1][2]. Specifically, it has shown promise in treating:

  • Locally advanced head and neck squamous cell carcinoma[2]
  • Oropharyngeal squamous cell carcinoma (cancer of the middle part of the throat)[4]

Current Clinical Trials

Several clinical trials are currently investigating the effectiveness of nimorazole in cancer treatment:

  • DAHANCA 30: This trial is studying whether a hypoxia gene profile can help predict which patients will benefit most from nimorazole treatment[1].
  • NIMRAD: This study is examining whether adding nimorazole to standard radiotherapy benefits patients with locally advanced head and neck squamous cell carcinoma who are not suitable for chemotherapy or certain antibody therapies[2].
  • AF CRT +/- Nimorazole in HNSCC: This trial is comparing the effectiveness of radiotherapy and chemotherapy with and without nimorazole in treating head and neck cancers[3].

How Nimorazole is Administered

Nimorazole is typically given as a pill in combination with radiotherapy. In clinical trials, it is often administered in the following way:

  • A dose of 1.2 g/m² (grams per square meter of body surface area) is given 90 minutes (plus or minus 30 minutes) before each radiotherapy session[3].
  • It is usually given no more than 5 times a week, even if radiotherapy is given 6 times a week[3].

Potential Benefits of Nimorazole

The addition of nimorazole to standard radiotherapy may offer several potential benefits:

  • Increased effectiveness of radiotherapy, particularly in hypoxic tumors[1].
  • Improved local control of the tumor, meaning better control of cancer growth at the original site[2].
  • Potentially improved survival rates and quality of life for patients with certain types of head and neck cancers[2][3].

Side Effects and Considerations

While nimorazole can potentially enhance the effectiveness of radiotherapy, it’s important to note that it may also come with side effects. The specific side effects and their severity can vary from person to person. Some clinical trials are specifically designed to assess the toxicity and side effects of nimorazole when used in combination with other treatments[3].

It’s crucial for patients to discuss the potential benefits and risks of nimorazole treatment with their healthcare provider. The decision to use nimorazole should be made on an individual basis, taking into account factors such as the specific type and stage of cancer, overall health status, and other available treatment options.

Aspect Details
Drug Name Nimorazole
Drug Class 5-nitroimidazoles, Radiosensitizer
Main Indication Head and neck squamous cell carcinoma (HNSCC)
Administration Oral pill, typically 1.2 g/m2 before radiation therapy
Key Trials DAHANCA 30, NIMRAD, AF CRT +/- Nimorazole in HNSCC
Primary Outcomes Locoregional control, Overall survival, Quality of life
Secondary Outcomes Disease-free survival, Distant metastasis, Toxicity
Special Focus Efficacy in hypoxic tumors, Gene profile-guided treatment

FAQ

  • What is nimorazole? Nimorazole is a drug that belongs to a class called 5-nitroimidazoles. It acts as a radiosensitizer, which means it makes tumor cells more sensitive to radiation therapy. It is being studied as a potential treatment for head and neck cancers.
  • How is nimorazole given to patients in clinical trials? In most trials, nimorazole is given as a pill that patients take before each radiation therapy session. The typical dose is 1.2 g/m2 taken 90 minutes before radiation treatment, up to 5 times per week during the course of radiation therapy.
  • What types of head and neck cancers are being studied with nimorazole? Nimorazole is primarily being studied in patients with head and neck squamous cell carcinoma (HNSCC), particularly those with locally advanced disease. Some trials focus specifically on oropharyngeal cancers.
  • What are the potential benefits of adding nimorazole to standard treatment? Researchers hope that adding nimorazole to standard radiation therapy and chemotherapy may improve tumor control and survival rates, especially for patients with more hypoxic (low oxygen) tumors. It may help make the radiation treatment more effective.
  • Are there any side effects associated with nimorazole? While specific side effects are still being studied in trials, nimorazole may cause some additional side effects when combined with radiation therapy. Trials are monitoring for both acute (short-term) and late (long-term) side effects to determine the drug's safety profile.

Ongoing Clinical Trials on Nimorazole

  • Study of Nimorazole Treatment Based on Hypoxia Profile in Head and Neck Cancer Patients Receiving Radiotherapy with Cisplatin

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Norway

Glossary

  • Head and neck squamous cell carcinoma (HNSCC): A type of cancer that begins in the squamous cells that line the moist surfaces inside the head and neck, such as the mouth, nose, and throat.
  • Hypoxia: A condition in which a region of the body or a tumor is deprived of adequate oxygen supply. Hypoxic tumor areas can be more resistant to radiation therapy.
  • Radiosensitizer: A substance that makes tumor cells more sensitive to radiation therapy, potentially improving the effectiveness of the treatment.
  • Intensity Modulated Radiation Therapy (IMRT): An advanced type of radiation therapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
  • Locoregional control: The prevention of cancer recurrence in the area where the original tumor was located (local) and in nearby lymph nodes (regional).
  • Oropharyngeal cancer: Cancer that develops in the part of the throat just behind the mouth, including the base of the tongue, tonsils, and soft palate.
  • Human Papillomavirus (HPV): A group of viruses that can cause certain types of cancer, including some head and neck cancers. HPV-positive cancers often have a better prognosis.
  • Quality of Life (QoL): A measure of an individual's overall well-being, including physical, emotional, and social functioning, especially important when evaluating cancer treatments.

References

  1. https://clinicaltrials.eu/trial/study-on-nimorazole-and-cisplatin-for-patients-with-head-and-neck-cancer-during-radiotherapy/
  2. https://clinicaltrials.gov/study/NCT01950689
  3. https://clinicaltrials.gov/study/NCT01880359
  4. https://clinicaltrials.gov/study/NCT04124198